ABSTRACT
Rocuronium bromide is an acetylcholine N2 receptor antagonist, which can be used as an auxiliary drug for general anesthesia. It has been reported that rocuronium has two possible metabolic pathways: N-dealkylation and O-deacetylation, which are mainly taken up by liver and excreted by bile in the form of primary drugs. In this paper, the metabolites of rocuronium in human bile were detected by UHPLC-QE-orbitrap-MS, thirteen metabolites were detected, including eleven phase I metabolites and two phase II metabolites, eleven of which had not been previously reported. At the same time, HEK293 cells overexpressing transporter were used to explore the transmembrane transport mechanism of rocuronium, the results showed that rocuronium was the substrate of MATE1, OCT1, OATP1B1 and OATP1B3. The above research results enrich the metabolic pathway of rocuronium in vivo, and put forward the possible transport mechanism of liver uptake and bile excretion, which can better guide the accurate and safe clinical drug application. The collection of human bile samples in this study was approved by the ethics committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (Approval Number: 2019-775-130-01).
ABSTRACT
Traditional Chinese medicine (TCM) syndrome, also known as TCM ZHENG or TCM pattern, is an integral and essential part of TCM theory that helps to guide the design of individualized treatments. A TCM syndrome, in essence, is a characteristic profile of all clinical manifestations in one patient that can be readily identified by a TCM practitioner. In this article, the authors reviewed the presentations of TCM syndromes in seven common malignancies (liver, lung, gastric, breast, colorectal, pancreatic and esophageal cancers), the objectivity and the standardization of TCM syndrome differentiation, the evaluation of TCM syndrome modeling in cancer research, and syndrome differentiation-guided TCM treatment of cancers. A better understanding of TCM syndrome theory, as well as its potential biological basis, may contribute greatly to the clinical TCM diagnosis and the treatment of cancer.
Subject(s)
Humans , Data Mining , Diagnosis, Differential , Medicine, Chinese Traditional , Neoplasms , Drug Therapy , Precision MedicineABSTRACT
Objective: To study the influence of preoperative transcatheter arterial chemoembolization (TACE) by selection on survival rate of resectable hepatocellular carcinoma (HCC) patients. Methods: Jan. 1996 to Jan. 1997, TACE was performed before surgery in 62 of 126 patients undergoing resection and the other 64 patients without TACE from. Results were retrospectively analyzed with regard to the changes of pathological examination after operation, recurrence rate and survival rate 1, 2, 3 years after operation. Results: Pathological examination showed that there were 13 total necrosis in TACE group, but no one in contrast group. There were no significant difference of recurrence rate 1, 3 years after operation between 2 groups. Recurrence rate 2 years after operation was 29.8% in TACE group, but 58.3% in contrast group. There were significant difference of recurrence rate 2 years after operation between 2 groups (P<0.05). Survival rate 3 years after operation was 54.4% in TACE group, but 33.3% in contrast group. Survival rate of TACE group was higher than that of contrast group (P<0.05). There were not significant difference of recurrence rate 1, 2 years after operation between 2 groups. Conclusion: Proper preoperative TACE for resectable HCC can improve the outcome of the operation to some extent.
ABSTRACT
Objective: To study the influence of preoperative transcatheter arterial chemoembolization (TACE) by selection on survival rate of resectable hepatocellular carcinoma (HCC) patients. Methods: Jan. 1996 to Jan. 1997, TACE was performed before surgery in 62 of 126 patients undergoing resection and the other 64 patients without TACE from. Results were retrospectively analyzed with regard to the changes of pathological examination after operation, recurrence rate and survival rate 1, 2, 3 years after operation. Results: Pathological examination showed that there were 13 total necrosis in TACE group, but no one in contrast group. There were no significant difference of recurrence rate 1, 3 years after operation between 2 groups. Recurrence rate 2 years after operation was 29.8% in TACE group, but 58.3% in contrast group. There were significant difference of recurrence rate 2 years after operation between 2 groups (P<0.05). Survival rate 3 years after operation was 54.4% in TACE group, but 33.3% in contrast group. Survival rate of TACE group was higher than that of contrast group (P<0.05). There were not significant difference of recurrence rate 1, 2 years after operation between 2 groups. Conclusion: Proper preoperative TACE for resectable HCC can improve the outcome of the operation to some extent.